{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Maintenance+Dose+Arm", "query": { "intervention": "Maintenance Dose Arm" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 702, "total_pages": 71, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Maintenance+Dose+Arm&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-08T06:48:58.140Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04104893", "title": "A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration Resistant Prostate Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 40, "start_date": "2020-02-20", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-09-08T06:48:58.140Z", "location_count": 13, "location_summary": "San Francisco, California • West Los Angeles, California • Washington D.C., District of Columbia + 10 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "West Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bay Pines", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04104893" }, { "nct_id": "NCT04958187", "title": "Study to Evaluate the Pharmacokinetics of ANG-3777 in Hemodialysis Subjects", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hemodialysis" ], "interventions": [ { "name": "ANG-3777", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Angion Biomedica Corp", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 16, "start_date": "2021-07", "completion_date": "2021-10", "has_results": false, "last_update_posted_date": "2021-07-15", "last_synced_at": "2026-09-08T06:48:58.140Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04958187" }, { "nct_id": "NCT03719664", "title": "Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "Albuvirtide", "type": "DRUG" }, { "name": "3BNC117", "type": "DRUG" }, { "name": "Baseline ART", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Frontier Biotechnologies Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2018-12-17", "completion_date": "2022-12", "has_results": false, "last_update_posted_date": "2021-09-29", "last_synced_at": "2026-09-08T06:48:58.140Z", "location_count": 7, "location_summary": "Palm Springs, California • San Francisco, California • Ft. Pierce, Florida + 4 more", "locations": [ { "city": "Palm Springs", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03719664" }, { "nct_id": "NCT01839955", "title": "Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Non-small Cell Lung Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Non-small Cell Lung Cancer" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "quinacrine dihydrochloride - Escalation dose", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "quinacrine dihydrochloride - Extension dose", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Neelesh Sharma MD PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2013-09", "completion_date": "2016-10", "has_results": false, "last_update_posted_date": "2016-10-31", "last_synced_at": "2026-09-08T06:48:58.140Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01839955" }, { "nct_id": "NCT02075255", "title": "Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Benralizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 220, "start_date": "2014-04-28", "completion_date": "2016-08-08", "has_results": true, "last_update_posted_date": "2018-06-08", "last_synced_at": "2026-09-08T06:48:58.140Z", "location_count": 20, "location_summary": "Los Angeles, California • Centennial, Colorado • Denver, Colorado + 16 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Centennial", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02075255" }, { "nct_id": "NCT02098993", "title": "Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Chest Syndrome", "Sickle Cell Disease" ], "interventions": [ { "name": "Unfractionated heparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Craig Seaman", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2014-05", "completion_date": "2018-06-27", "has_results": true, "last_update_posted_date": "2019-07-16", "last_synced_at": "2026-09-08T06:48:58.140Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02098993" }, { "nct_id": "NCT00103285", "title": "Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Childhood B Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "3-Dimensional Conformal Radiation Therapy", "type": "RADIATION" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "9 Years", "sex": "ALL", "summary": "1 Year to 9 Years" }, "enrollment_count": 5377, "start_date": "2005-04-11", "completion_date": "2021-03-31", "has_results": true, "last_update_posted_date": "2021-06-14", "last_synced_at": "2026-09-08T06:48:58.140Z", "location_count": 210, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00103285" }, { "nct_id": "NCT06052059", "title": "A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "IV Tulisokibart", "type": "DRUG" }, { "name": "IV Placebo", "type": "DRUG" }, { "name": "SC Tulisokibart", "type": "DRUG" }, { "name": "SC Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "16 Years to 80 Years" }, "enrollment_count": 1020, "start_date": "2023-10-25", "completion_date": "2029-08-01", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-09-08T06:48:58.140Z", "location_count": 76, "location_summary": "Dothan, Alabama • Fairhope, Alabama • Litchfield Park, Arizona + 65 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Litchfield Park", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06052059" }, { "nct_id": "NCT07600697", "title": "Suzetrigine for Opioid-Sparing Postoperative Analgesia Following Transvaginal Pelvic Reconstructive Surgery", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pelvic Organ Prolapse (POP)", "Stress Urinary Incontinence (SUI)", "Postoperative Pain" ], "interventions": [ { "name": "Suzetrigine", "type": "DRUG" }, { "name": "Opioid Analgesics (Tramadol or Oxycodone)", "type": "DRUG" }, { "name": "Scheduled Acetaminophen and Ibuprofen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 120, "start_date": "2026-07-01", "completion_date": "2028-07-01", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-09-08T06:48:58.140Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07600697" }, { "nct_id": "NCT01236560", "title": "Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Brain Stem Glioma", "Cerebral Astrocytoma", "Childhood Cerebellar Anaplastic Astrocytoma", "Childhood Cerebral Anaplastic Astrocytoma", "Childhood Spinal Cord Neoplasm" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 101, "start_date": "2011-01-26", "completion_date": "2023-12-31", "has_results": true, "last_update_posted_date": "2024-02-20", "last_synced_at": "2026-09-08T06:48:58.140Z", "location_count": 124, "location_summary": "Birmingham, Alabama • Downey, California • Loma Linda, California + 98 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Downey", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01236560" } ] }